|
BioWorld by Clarivate Explores the Future of CAR T Therapy in Mainland China in Special Report
Wednesday, May 8, 2024
Three-part report investigates rapid pipeline growth, partnerships, clinical trials, and patient access challenges in cancer treatment
LONDON, April 30, 2024 /PRNewswire/ -- BioWorld(TM) published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, explores the growing investment in CAR T therapy development in mainland China in a new series titled "China's CAR T market comes of age." The report examines the dynamic realm of CAR T-cell therapies in China, including the rapid pipeline growth, deals, clinical trials and challenging issues surrounding patient access to very expensive and effective cancer therapeutics.
CAR T (Chimeric Antigen Receptor T-cell) therapy represents a revolutionary approach to cancer treatment, harnessing the power of the body's immune system to target and destroy cancer cells. As this groundbreaking treatment gains traction in the pharmaceutical sphere, the BioWorld special report provides valuable insights into its present state and future potential. The report, authored by Tamra Sami, Ruchita Kumar, and Sahil Arora, covers three key topics:
-- Part One: China's investigator trials accelerate competitive CAR T
developmentThe exponential growth of China's CAR T market is projected
to soar from $72 million in 2022 to an impressive $342 million over the
next decade. With over 400 CAR T therapies currently in the pipeline,
fueled by strategic collaborations between multinational pharma giants
and local biotechs, this segment promises unprecedented opportunities
for growth and innovation.
-- Part Two: CAR T pipelines bloom to treat world's largest cancer
populationAs of Jan. 31, 2024, there were more than 300 CAR T trials
registered in China, surpassing the U.S. and becoming the country with
the most CAR T therapy clinical trials. Among them, CD19 is the most
frequently studied target. The rapid evolution of CAR T-cell therapies
in China has escalated over the past decade from the start of the first
clinical trials in 2013 to the country becoming an established host for
CAR T-cell-related trials by 2017.
-- Part Three: China grapples with providing access to CAR T therapiesThe
process of manufacturing autologous T-cell therapies is technically
challenging when compared with other oncology drugs, making the overall
cost of developing CAR T therapies significantly higher. A challenging
reimbursement environment for drugs in China also means that most
patients will have to pay out of pocket to access CAR T therapies. Taken
together, complex logistics - production, manufacturing and supply chain
- and complicated administration requirements are key bottlenecks that
inflate the input costs involved in developing these specialized
treatment options.
Lynn Yoffee, Publisher, BioWorld, said: "China's quest to become the world leader in biopharmaceutical innovation may be gaining momentum even as countries sort through complex licensing and patent rights challenges. One thing is clear: China is now the leader in studying CAR T therapies with the most clinical trials, surpassing the U.S. How patients will be able to pay for these expensive treatments out of pocket given China's challenging reimbursement system remains in question. The BioWorld special report investigates how CAR T development is coming of age in a country with the world's second-largest population."
For more exclusive in-depth coverage of the evolution of China's CAR T landscape, visit here.
Join the conversation and mention BioWorld on X and LinkedIn as well as Clarivate for Life Sciences & Healthcare on X and LinkedIn.
About BioWorld
With writers and editors stationed around the globe, BioWorld published by Clarivate, reports the breaking news - and provides key perspective on hundreds of therapeutics and devices in development, the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes. BioWorld has a long tradition of excellence in journalism. Collectively, the news services have been honored with 61 awards dating back to 1998.
About Clarivate
Clarivate(TM) is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
Media Contact:
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
newsroom@clarivate.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bioworld-by-clarivate-explores-the-future-of-car-t-therapy-in-mainland-china-in-special-report-302130695.html
SOURCE Clarivate Plc
|
|
|
|
|
|
 |
The New Identity Theft Crisis: AI Scams, Child Victims, and Credit Damage Are All Spiking | Jan 22, 2026
|
|
AllSci Launches Hypothesis Publishing: A Seamless Way to Share, Connect, and Advance Scientific Ideas | Jan 22, 2026
|
|
Canadian Fintech Tuhk Inc., Founded by Ethoca and NuData Security Veterans, Raises US$6 Million Seed Round Led by FINTOP, with Lloyds Banking Group and Capital One Ventures | Jan 22, 2026
|
|
Darwin CX Caps a Banner Year with AI Launch, Sold-Out Events, and Industry Book Launch | Jan 22, 2026
|
|
Fintech Startup BON Credit Secures $3.5 Million In Funding | Jan 22, 2026
|
|
PayDo Launches Unified Payment Infrastructure Suite for Digital Businesses | Jan 22, 2026
|
|
Nudge Security Unveils Industry's Most Comprehensive AI Security Governance Platform | Jan 22, 2026
|
|
IoTeX Publishes MiCA-Compliant Whitepaper for IOTX, Enabling EU-Wide Alignment Under the New Regulatory Framework | Jan 22, 2026
|
|
Gametime Launches "12 Days of Gametime" Holiday Giveaway in Partnership with Barstool Sports | Jan 22, 2026
|
|
TSX Venture Exchange Market Data Now Available Across Over 40 Blockchains via Chainlink | Jan 22, 2026
|
|
|
|
